Iterum Therapeutics Stock Shoots Higher As Sulopenem Application Review On Track
Iterum Therapeutics concluded a late-cycle FDA meeting for sulopenem etzadroxil/probenecid, aimed at treating uncomplicated UTIs in patients with quinolone non-susceptible pathogens. The FDA deemed an Advisory Committee meeting unnecessary, targeting a July 25 action date. ITRM shares rose 22.8% to $1.51 premarket.
Reference News
Iterum Therapeutics Stock Shoots Higher As Sulopenem Application Review On Track
Iterum Therapeutics concluded a late-cycle FDA meeting for sulopenem etzadroxil/probenecid, aimed at treating uncomplicated UTIs in patients with quinolone non-susceptible pathogens. The FDA deemed an Advisory Committee meeting unnecessary, targeting a July 25 action date. ITRM shares rose 22.8% to $1.51 premarket.